# CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

Source: https://onco.cc/trials/nct05251714/  
OnCo record `nct05251714` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant in advanced solid tumours, run by Treadwell Therapeutics, Inc, active and no longer recruiting.

## Summary

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer is a phase 1/2 interventional study registered as NCT05251714 by Treadwell Therapeutics, Inc, with 44 participants enrolled, started 2022-05-27 and due to reach its primary completion in 2026-08. Interventions recorded: CFI-402257 and Fulvestrant.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05251714
- Phase: 1/2
- Setting: A Dose-confirming Study of CFI-402257 as a Single Agent in Advanced Solid Tumors and in Combination With Fulvestrant in Patients With ER+/HER2- Advanced Breast Cancer After Disease Progression on Prior CDK4/6 and Endocrine Therapy
- Sponsor: Treadwell Therapeutics, Inc
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT05251714: https://clinicaltrials.gov/study/NCT05251714

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05251714.json